Compare PASG & MODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PASG | MODD |
|---|---|---|
| Founded | 2017 | 1998 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0M | 23.5M |
| IPO Year | 2020 | 2019 |
| Metric | PASG | MODD |
|---|---|---|
| Price | $5.20 | $4.39 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | ★ 64.6K | 18.4K |
| Earning Date | 05-12-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.62 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $0.12 |
| 52 Week High | $20.00 | $6.16 |
| Indicator | PASG | MODD |
|---|---|---|
| Relative Strength Index (RSI) | 42.65 | 59.08 |
| Support Level | $3.94 | $0.41 |
| Resistance Level | $5.74 | $6.04 |
| Average True Range (ATR) | 0.38 | 0.43 |
| MACD | 0.18 | -0.01 |
| Stochastic Oscillator | 69.53 | 87.94 |
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.